Sulfacarbamide
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 571122

CAS#: 547-44-4 (free base)

Description: Sulfacarbamide is a antimicrobial agent that has been investigated as a therapeutic biochemical for diabetes treatment. It may lower blood sugar.


Chemical Structure

img
Sulfacarbamide
CAS# 547-44-4 (free base)

Theoretical Analysis

MedKoo Cat#: 571122
Name: Sulfacarbamide
CAS#: 547-44-4 (free base)
Chemical Formula: C7H9N3O3S
Exact Mass: 215.04
Molecular Weight: 215.230
Elemental Analysis: C, 39.06; H, 4.22; N, 19.52; O, 22.30; S, 14.90

Price and Availability

Size Price Availability Quantity
1g USD 385
Bulk inquiry

Related CAS #: 4675-90-5 (Na); 547-44-4 (free base)  

Synonym: Sulfacarbamide; Uramid; Sulfanilylurea

IUPAC/Chemical Name: Benzenesulfonamide, 4-amino-N-(aminocarbonyl)- (9CI)

InChi Key: WVAKABMNNSMCDK-UHFFFAOYSA-N

InChi Code: InChI=1S/C7H9N3O3S/c8-5-1-3-6(4-2-5)14(12,13)10-7(9)11/h1-4H,8H2,(H3,9,10,11)

SMILES Code: O=S(C1=CC=C(N)C=C1)(NC(N)=O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 215.23 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Otto W, Woraschk HJ, Mlytz H. [Placental passage of sulfacarbamide]. Zentralbl Gynakol. 1971 Apr 24;93(17):552-7. German. PubMed PMID: 5577004.

2: Bruun JN, Ostby N, Bredesen JE, Kierulf P, Lunde PK. Sulfonamide and trimethoprim concentrations in human serum and skin blister fluid. Antimicrob Agents Chemother. 1981 Jan;19(1):82-5. PubMed PMID: 7247364; PubMed Central PMCID: PMC181361.

3: Kowalski P, Plenis A, Oledzka I, Konieczna L. Optimization and validation of the micellar electrokinetic capillary chromatographic method for simultaneous determination of sulfonamide and amphenicol-type drugs in poultry tissue. J Pharm Biomed Anal. 2011 Jan 5;54(1):160-7. doi: 10.1016/j.jpba.2010.08.005. Epub 2010 Aug 17. PubMed PMID: 20817447.

4: LANGECKER H, SCHULZE E. [Distribution of sulfanilic acid, sulfanilamide and sulfacarbamide in the blood, cerebrospinal fluid, aqueous humor and pericardial fluid in adrenalectomized dog. II. Dynamics of distribution]. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1954;221(2):160-5. Undetermined Language. PubMed PMID: 13154430.

5: Bergan T, Bruun JN, Ostby N, Bredesen JE, Lunde PK. Human pharmacokinetics and skin blister levels of sulfonamides and dihydrofolate reductase inhibitors. Chemotherapy. 1986;32(4):319-28. PubMed PMID: 3731918.

6: Guldsten H. Clindamycin and sulphonamides in the treatment of ocular toxoplasmosis. Acta Ophthalmol (Copenh). 1983 Feb;61(1):51-7. PubMed PMID: 6858644.

7: Hładoń T. [Physico-chemical studies on adsorptive properties of pharmaceutic aids used in pharmaceutical technology. II. Mechanism of adsorption of sulfonamides on Veegum]. Acta Pol Pharm. 1981;38(2):229-35. Polish. PubMed PMID: 7315467.

8: PENCHEV I, POPOV A, KOLAROV P, ANDREEV D. [Sulfanilylurea therapy of diabetes mellitus]. Probl Endokrinol Gormonoter. 1958 Nov-Dec;4(6):20-8. Russian. PubMed PMID: 13633935.

9: POGOZHEVA LN. [Sulfanilylurea in the control of urinary infections]. Sov Med. 1951 Mar;3:23-4. Undetermined Language. PubMed PMID: 14817507.

10: Vicentini CB, Guarneri M, Sarto G. Hypoglycemic compounds. Sulfanilylurea derivatives containing amino acids and dipeptides. I. Farmaco Sci. 1983 Aug;38(8):595-602. PubMed PMID: 6617854.

11: BRETAN M, KAMMERER L. [Insulin-like activity of the plasma during Bucarban treatment. (Data on the mechanism of action of the sulfanilylureas)]. Orv Hetil. 1962 Oct 21;103:1981-5. Hungarian. PubMed PMID: 14015308.

12: Tret'iakova LF, Kochergin IuV. [Moderately mineralized (Obukhovskaia) mineral water and urosulfan electrophoresis in the treatment of children with pyelonephritis]. Vopr Kurortol Fizioter Lech Fiz Kult. 1984 Sep-Oct;(5):45-7. Russian. PubMed PMID: 6239446.

13: KALDOR A, POGATSA G. [The effect of sulfanilylurea preparations on the glucose release of the liver]. Orv Hetil. 1962 Oct 21;103:1985-6. Hungarian. PubMed PMID: 13961902.

14: Baranov VG, Gasparian EG. [Disputable problems of the effect of sulfanilylurea derivatives in patients with diabetes mellitus and perspectives on their use]. Probl Endokrinol (Mosk). 1983 Jan-Feb;29(1):3-7. Russian. PubMed PMID: 6340092.

15: DECOURTJUNIOR C. [EXPERIENCES WITH AN ASSOCIATION OF FORMO-PHTHALYL-SULFANILYLUREA AND NEOMYCIN IN INTESTINAL THERAPY]. Hospital (Rio J). 1964 Jun;65:1225-36. Portuguese. PubMed PMID: 14172856.

16: WILD H, LINDEN HW. [Clinical observations on injuries to the peripheral nervous system and liver in diabetics receiving sulfanilylurea]. Dtsch Med J. 1959 Jun 5;10(8):286-92. German. PubMed PMID: 13671990.